Julia Agne, Arnab Basu, Kimberley Lee, Yuxuan Wang receive NCCN Young Investigator Award

World Cancer Day 2025: A symbol of personal and collective uncertainty

My entire life I was told to respectfully question anything and everything, because questions equal answers, which provide understanding and thereby comfort—even with the uncomfortable. It’s simply in my DNA.

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

The National Comprehensive Cancer Network published its first patient resource aimed at informing people about the latest recommendations around hereditary and familial cancer risk. The document provides guidance on testing for inherited genetic mutations that can raise the risk of cancer.

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

The National Comprehensive Cancer Network included circulating tumor DNA testing in their Clinical Practice Guidelines in Oncology for diffuse large B-cell lymphoma. This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care.

January 17, 2025

Vol.51 No.02

Clinical Roundup

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

The National Comprehensive Cancer Network updated its chronic myeloid leukemia treatment guidelines, recommending Scemblix (asciminib) for the treatment of adults with newly diagnosed Ph+ CML-CP as a category 1-preferred.

November 22, 2024

Vol.50 No.44

Drugs & Targets

NCCN adds Lymphir to Clinical Practice Guidelines in Oncology

The National Comprehensive Cancer Network added Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy, to the NCCN Clinical Practice Guidelines in Oncology. Lymphir is included based on an NCCN Category 2A recommendation which indicates a uniform NCCN consensus that the drug is appropriate as an option for patients with CTCL.

September 06, 2024

Vol.50 No.33

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

July 19, 2024

Vol.50 No.29

By Jacquelyn Cobb

Julia Agne, Arnab Basu, Kimberley Lee, Yuxuan Wang receive NCCN Young Investigator Award

YOU MAY BE INTERESTED IN

World Cancer Day 2025: A symbol of personal and collective uncertainty

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

NCCN adds Lymphir to Clinical Practice Guidelines in Oncology

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Renew today!

Subscriber content

Julia Agne, Arnab Basu, Kimberley Lee, Yuxuan Wang receive NCCN Young Investigator Award

YOU MAY BE INTERESTED IN

World Cancer Day 2025: A symbol of personal and collective uncertainty

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

NCCN adds Lymphir to Clinical Practice Guidelines in Oncology

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”